SWOT Analysis for Zevra Therapeutics Inc

Relative Outperformance versus Industry over 1 Year
PEG lower than Industry PEG
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Stock with Low PE (PE < = 10)

Stocks with Quarter Change % less than Industry
Companies with High Debt
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Biggest Price Losers from Open
Top Losers
Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Weak Momentum: Price below Short, Medium and Long Term Averages
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
Declining profits every quarter for the past 3 quarters
Companies Increasing Debt as per Annual Report
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter